In Myleloma, New Drugs, Skyrocketing Price Tags

In Myeloma, New Drugs, Skyrocketing Price Tags

In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which are often described as “skyrocketing.” CEOs from AbbVie, AstraZeneca, Bristol-Myers Squibb,...

Online Exclusives

Trump Administration Ends Fetal Tissue Research at NIH

In the latest in a string of decisions pleasing to anti-abortion groups, the Trump administration announced sharp cuts to federal spending on fetal-tissue research,...

Gene Modified in Chinese “CRISPR Babies” Associated with Premature Death

A new study in Nature Medicine indicates that the gene that He Jiankui, PhD, modified in twin baby girls to mitigate HIV risk in...

News

From the Blood Journals

WIB_icon

Walking Speed Predicts Frailty, Survival, and Other Outcomes in Older Patients...

Walking speed was a reliable indicator of frailty among older patients with blood cancers, and this frailty measure was a more accurate predictor of...

Hematologic Malignancies Drive In-Hospital Death Rates

In the past 17 years, the overall rate of in-hospital deaths among patients with hematologic malignancies has decreased by 30 percent, with a corresponding...

Multimedia

Robert Kreitman: Delayed Versus Concurrent Rituximab in Hairy Cell Leukemia

Robert Kreitman, MD, shares results from a new study suggesting patients with hairy cell leukemia should receive rituximab concurrently with frontline cladribine.

Tibor Kovacsovics: CX-01 Associated With High Response Rates in Older Patients...

Tibor Kovacsovics, MD, discusses CX-01, a heparin derivative that induced high response rates in older patients newly diagnosed with acute myeloid leukemia.

Paul Richardson: Isatuximab Improves PFS in Relapsed/Refractory Myeloma

Paul Richardson, MD, shares results seen with isatuximab in heavily refractory myeloma, and discusses how this new agent compares with approved monoclonal antibodies.

Iman Abou Dalle: Leuprolide Improves Post-Chemotherapy Recovery in Patients With Leukemia

Iman Abou Dalle, MD, describes how blocking luteinizing hormone receptors with leuprolide can improve hematopoietic recovery in patients with leukemia who have undergone intensive...

On Location

On location

Daratumumab Combination Induces High Response Rates in AL Amyloidosis

In one-year follow-up data from the phase III ANDROMEDA trial, the combination of subcutaneous daratumumab...
On location

Evaluating PRM-151 in Patients With Myelofibrosis Resistant or Intolerant to Ruxolitinib

According to results from a double-blind, phase II study, PRM-151 improved bone marrow fibrosis severity,...
On location

Should Guadecitabine Be the HMA of Choice in Acute Myeloid Leukemia?

Results from a large phase III trial of the hypomethylating agent (HMA) guadecitabine in patients...
On location

Can Women With CML Safely Continue TKIs During Pregnancy?

Most women with chronic myeloid leukemia (CML) who received treatment with tyrosine kinase inhibitors (TKIs)...
On location

Nivolumab Associated With High Response Rates in Relapsed/Refractory PMBL

Nearly three-quarters of patients with relapsed/refractory primary mediastinal large B-cell lymphoma (PMBL) responded to treatment...
On location

Single-Agent Acalabrutinib Improves Survival in Relapsed/Refractory Chronic Lymphocytic Leukemia

According to results from the phase III ASCEND trial, treatment with acalabrutinib as a single...

Latest Headlines

Advertisement

ASH Directions

ASH Directions

2020 Brings New Editor-in-Chief for ASH Clinical News, and more

Learn About Legislation and Health Policy from the ASH Advocacy Leadership Institute! This October marks the ninth annual ASH Advocacy Leadership Institute (ALI): An opportunity...
ASH Directions

Seventh Edition of ASH-SAP Coming Soon, CDC Responds to ASH’s Concerns About Opioid Guidelines

CDC Clarifies Opioid Prescribing Guideline at Urging of Hematology and Oncology GroupsHematologists, especially sickle cell disease (SCD) specialists, are welcoming a recent clarification from...

Sign up for our
eNewsletter!

The Society Pages

Remembering Milton H. Freedman, Caryn Lerman Named Director of USC Norris, and More

Remembering Milton H. Freedman (1919 – 2019) Milton H. Freedman, MD, the first hematologist to open a private practice in Atlanta, died on January 21,...
The Society Pages

Remembering Arthur Rosenberg, Dorothy Tuan Lo, and more

Remembering Arthur Rosenberg (1935 – 2018) Arthur Rosenberg, MD, FRCPC, a former chief of hematology at the Jewish General Hospital (JGH) in Montreal, Quebec, passed...
The Society Pages

Remembering Francesco Lo Coco, NYU Langone Health to Establish Center for Blood Cancers, and...

Remembering Francesco Lo Coco (1955 – 2019)  Francesco Lo Coco, MD, a renowned leukemia researcher and pioneer of targeted therapy, passed away on March 3,...
In Myleloma, New Drugs, Skyrocketing Price Tags

In Myeloma, New Drugs, Skyrocketing Price Tags

In late February, seven pharmaceutical executives were called before the U.S. Senate Finance Committee to testify about the prices of brand-name prescription drugs, which...

Resurrecting the House Call

New at-home strategies for hematologic conditions offer improved outcomes and patient satisfaction Physician home visits have become a thing of the past: Nearly a century...

CMML: A Unique Overlap Syndrome Receiving Increased Attention

For many years, chronic myelomonocytic leukemia (CMML) has been treated as a form of myelodysplastic syndrome (MDS), despite its unique clinical and biological characteristics. “Everyone...